Log in

Zimmer Biomet Stock Forecast, Price & News

+0.34 (+0.23 %)
(As of 11/27/2020 12:00 AM ET)
Today's Range
Now: $150.02
50-Day Range
MA: $144.11
52-Week Range
Now: $150.02
Volume381,674 shs
Average Volume1.43 million shs
Market Capitalization$31.10 billion
P/E Ratio937.68
Dividend Yield0.64%
Zimmer Biomet Holdings, Inc., together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental. The company provides orthopaedic reconstructive products, such as knee and hip replacement products; S.E.T. products, including surgical, sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products; and bone cement and office based technology products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
Read More
Zimmer Biomet logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 2.8Dividend Strength: 1.7Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.08 out of 5 stars

Industry, Sector and Symbol

Industry Surgical appliances & supplies



Sales & Book Value

Annual Sales$7.98 billion
Cash Flow$13.88 per share
Book Value$60.25 per share


Net Income$1.13 billion


Market Cap$31.10 billion
Next Earnings Date2/2/2021 (Estimated)
+0.34 (+0.23 %)
(As of 11/27/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ZBH News and Ratings via Email

Sign-up to receive the latest news and ratings for ZBH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Zimmer Biomet (NYSE:ZBH) Frequently Asked Questions

How has Zimmer Biomet's stock price been impacted by Coronavirus (COVID-19)?

Zimmer Biomet's stock was trading at $111.19 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ZBH shares have increased by 34.9% and is now trading at $150.02.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Zimmer Biomet?

24 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zimmer Biomet in the last year. There are currently 1 sell rating, 5 hold ratings, 16 buy ratings and 2 strong buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Zimmer Biomet

What stocks does MarketBeat like better than Zimmer Biomet?

Wall Street analysts have given Zimmer Biomet a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Zimmer Biomet wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Zimmer Biomet's next earnings date?

Zimmer Biomet is scheduled to release its next quarterly earnings announcement on Tuesday, February 2nd 2021.
View our earnings forecast for Zimmer Biomet

How were Zimmer Biomet's earnings last quarter?

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) released its quarterly earnings data on Wednesday, November, 11th. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.07 by $0.74. The medical equipment provider earned $1.92 billion during the quarter, compared to the consensus estimate of $1.71 billion. Zimmer Biomet had a return on equity of 10.07% and a net margin of 0.52%. The firm's revenue for the quarter was up 1.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.77 EPS.
View Zimmer Biomet's earnings history

How often does Zimmer Biomet pay dividends? What is the dividend yield for Zimmer Biomet?

Zimmer Biomet declared a quarterly dividend on Thursday, September 10th. Stockholders of record on Wednesday, September 30th will be given a dividend of $0.24 per share on Friday, October 30th. This represents a $0.96 annualized dividend and a dividend yield of 0.64%. The ex-dividend date is Tuesday, September 29th.
View Zimmer Biomet's dividend history

What price target have analysts set for ZBH?

24 brokers have issued 12-month price objectives for Zimmer Biomet's stock. Their forecasts range from $106.00 to $177.00. On average, they anticipate Zimmer Biomet's share price to reach $152.57 in the next twelve months. This suggests a possible upside of 1.7% from the stock's current price.
View analysts' price targets for Zimmer Biomet

Are investors shorting Zimmer Biomet?

Zimmer Biomet saw a decline in short interest in the month of October. As of October 30th, there was short interest totaling 2,130,000 shares, a decline of 16.5% from the October 15th total of 2,550,000 shares. Based on an average trading volume of 1,010,000 shares, the days-to-cover ratio is currently 2.1 days.
View Zimmer Biomet's Short Interest

Who are some of Zimmer Biomet's key competitors?

What other stocks do shareholders of Zimmer Biomet own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zimmer Biomet investors own include AT&T (T), The Walt Disney (DIS), Johnson & Johnson (JNJ), Bristol-Myers Squibb (BMY), Cisco Systems (CSCO), Merck & Co., Inc. (MRK), Intel (INTC), AbbVie (ABBV), NVIDIA (NVDA) and JPMorgan Chase & Co. (JPM).

Who are Zimmer Biomet's key executives?

Zimmer Biomet's management team includes the following people:
  • Mr. Bryan C. Hanson, Pres, CEO & Director (Age 53, Pay $2.88M)
  • Mr. Suketu P. Upadhyay, Exec. VP & CFO (Age 51, Pay $2.2M)
  • Mr. Sang Yi, Pres of Asia Pacific (Age 58, Pay $1.21M)
  • Mr. Didier Deltort, Pres of Europe, Middle East & Africa (Age 53, Pay $1.24M)
  • Mr. Ivan Tornos, Group Pres of Global Bus.es & Americas (Age 44, Pay $1.9M)
  • Mr. Kenneth R. Tripp, Sr. VP of Global Operations & Logistics
  • Ms. Carrie A. Nichol CPA, VP, Controller & Chief Accounting Officer (Age 41)
  • Mr. Zeeshan Tariq, VP & Chief Information Officer
  • Ms. Keri P. Mattox, Sr. VP of Investor Relations & Chief Communications Officer
  • Mr. Chad F. Phipps, Sr. VP, Gen. Counsel & Sec. (Age 48)

What is Zimmer Biomet's stock symbol?

Zimmer Biomet trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZBH."

Who are Zimmer Biomet's major shareholders?

Zimmer Biomet's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.56%), Massachusetts Financial Services Co. MA (4.90%), JPMorgan Chase & Co. (4.71%), State Street Corp (4.13%), Boston Partners (1.43%) and Ceredex Value Advisors LLC (0.51%). Company insiders that own Zimmer Biomet stock include Arthur J Higgins, Aure Bruneau, Betsy J Bernard, Bryan C Hanson, Chad F Phipps, Didier Deltort, Michael J Farrell, Michael W Michelson, Sang Yi and Syed A Jafry.
View institutional ownership trends for Zimmer Biomet

Which major investors are selling Zimmer Biomet stock?

ZBH stock was sold by a variety of institutional investors in the last quarter, including Boston Partners, State Street Corp, AXA S.A., Cubist Systematic Strategies LLC, AQR Capital Management LLC, Massachusetts Financial Services Co. MA, State of Tennessee Treasury Department, and Neuberger Berman Group LLC.
View insider buying and selling activity for Zimmer Biomet

Which major investors are buying Zimmer Biomet stock?

ZBH stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., JPMorgan Chase & Co., Polar Capital LLP, Polar Capital LLP, Alleghany Corp DE, Great West Life Assurance Co. Can, Ceredex Value Advisors LLC, and Wedge Capital Management L L P NC. Company insiders that have bought Zimmer Biomet stock in the last two years include Arthur J Higgins, Betsy J Bernard, Bryan C Hanson, Michael J Farrell, Michael W Michelson, and Syed A Jafry.
View insider buying and selling activity for Zimmer Biomet

How do I buy shares of Zimmer Biomet?

Shares of ZBH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Zimmer Biomet's stock price today?

One share of ZBH stock can currently be purchased for approximately $150.02.

How big of a company is Zimmer Biomet?

Zimmer Biomet has a market capitalization of $31.10 billion and generates $7.98 billion in revenue each year. The medical equipment provider earns $1.13 billion in net income (profit) each year or $7.87 on an earnings per share basis. Zimmer Biomet employs 19,900 workers across the globe.

What is Zimmer Biomet's official website?

The official website for Zimmer Biomet is www.zimmerbiomet.com.

How can I contact Zimmer Biomet?

Zimmer Biomet's mailing address is 345 EAST MAIN STREET, WARSAW IN, 46580. The medical equipment provider can be reached via phone at 574-267-6131 or via email at [email protected]

This page was last updated on 11/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.